Pre-made Dilpacimab benchmark antibody ( Bispecific mAb, anti-DLL4;VEGFA therapeutic antibody, Anti-AOS6/delta4/hdelta2;VPF/VEGF/MVCD1 Antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-ab-145

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-ab-145 Category Tags ,

Product Details

Pre-Made Dilpacimab biosimilar, Bispecific mAb, Anti-DLL4;VEGFA Antibody: Anti-AOS6/delta4/hdelta2;VPF/VEGF/MVCD1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Products Name (INN Index)

Pre-Made Dilpacimab biosimilar, Bispecific mAb, Anti-DLL4;VEGFA Antibody: Anti-AOS6/delta4/hdelta2;VPF/VEGF/MVCD1 therapeutic antibody

INN Name

Dilpacimab

Target

DLL4,VEGFA

Format

Bispecific mAb

Derivation

Bispecific antibody

Species Reactivity

Human

CH1 Isotype

IgG1

VD LC

Kappa,Kappa

Highest_Clin_Trial (Jan '20)

Phase-II

Est. Status

Active

100% SI Structure

None;1bj1:HL:KJ

99% SI Structure

None;None

95-98% SI Structure

None;6bft:HL:AB/1cz8:HL:YX

Year Proposed

2018

Companies

AbbVie

Conditions Approved

NA

Conditions Active

Colorectal cancer,Solid tumours

Conditions Discontinued

NA

Development Tech

NA

Previous Name

NA

Gm Offical Target Name

DLL4,VEGFA

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide